Matthew J Niederst

Matthew J Niederst

UNVERIFIED PROFILE

Are you Matthew J Niederst?   Register this Author

Register author
Matthew J Niederst

Matthew J Niederst

Publications by authors named "Matthew J Niederst"

Are you Matthew J Niederst?   Register this Author

20Publications

895Reads

46Profile Views

Distinct evolutionary paths to TKI resistance in NSCLC.

Cell Cycle 2018 29;17(3):298-299. Epub 2018 Jan 29.

a Massachusetts General Hospital Cancer Center , Charlestown , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384101.2016.1
Publisher Site
http://dx.doi.org/10.1080/15384101.2016.1221024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914907PMC
September 2019

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

JAMA Oncol 2016 Apr;2(4):541-3

Massachusetts General Hospital Cancer Center, Boston2Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.5009DOI Listing
April 2016

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Clin Cancer Res 2015 Sep 11;21(17):3924-33. Epub 2015 May 11.

Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587765PMC
September 2015

Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.

Lancet Oncol 2015 Jul;16(7):e309-10

Massachusetts General Hospital Cancer Center, Department of Medicine and Harvard Medical School, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00058-3DOI Listing
July 2015

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Lancet Oncol 2015 Apr;16(4):e165-72

Massachusetts General Hospital Cancer Center, Department of Medicine and Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)71180-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470698PMC
April 2015

EMT twists the road to PI3K.

Cancer Discov 2014 Feb;4(2):149-51

Department of Medicine and Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918580PMC
February 2014

Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.

Sci Signal 2013 Sep 24;6(294):re6. Epub 2013 Sep 24.

1Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.2004652DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876281PMC
September 2013

Suppression of survival signalling pathways by the phosphatase PHLPP.

FEBS J 2013 Jan 16;280(2):572-83. Epub 2012 Mar 16.

Biomedical Sciences Graduate Program, University of California, San Diego, CA 92093-0721, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1742-4658.2012.08537.x
Publisher Site
http://dx.doi.org/10.1111/j.1742-4658.2012.08537.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770140PMC
January 2013